Business Wire

Burjeel Holdings Lights Up Burj Khalifa With New Campaign Featuring Shah Rukh Khan

29.9.2022 12:27:00 EEST | Business Wire | Press release

Share

A month ahead of his birthday, Indian actor Shah Rukh Khan lit up the world’s tallest building, The Burj Khalifa, on Wednesday evening, in a brand campaign for the UAE-based conglomerate Burjeel Holdings. For the past few years, on Shah Rukh Khan’s birthday, the Burj Khalifa has lit up in honor of the superstar.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005378/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The brand campaign of Burjeel Holdings featuring Shah Rukh Khan premiering at Burj Khalifa on Wednesday evening (Photo: AETOSWire)

Shah Rukh Khan is the face of the group that owns 39 hospitals and medical centers under the Burjeel, Medeor, LLH, Lifecare, and Tajmeel brands in the UAE and Oman.

The campaign, ‘We Are Committed To Your Care’, which is set to appear region-wide on multiple platforms features the Abu Dhabi-headquartered healthcare powerhouse’s homegrown success story. It is based on the group’s vision of connecting care, scale & community in health.

The video begins with Shah Rukh Khan’s tribute to the UAE’s heroic martyrs at the national and cultural landmark of Wahat Al Karama. The 70-second video also showcases the iconic Sheikh Zayed Grand Mosque and the group's flagship facility, Burjeel Medical City.

“Sheikh Zayed Grand Mosque and Wahat Al Karama depict the essence of the UAE and reflect Abu Dhabi’s growth into a global hub. The video draws parallels between the ideals that inspired these landmarks and Burjeel Holdings’ ethos of serving the community,” said Mr. Prashant Issar, Director of the campaign video, who also directed the Dubai Tourism campaign featuring Shah Rukh Khan.

Dr. Shamsheer Vayalil, Chairman of Burjeel Holdings, said, “We are proud to launch the campaign with superstar Shah Rukh Khan that epitomizes the values we cherish. It symbolizes Burjeel Holdings’ ambition to become a global leader in healthcare based out of a country that has inspired the world with its fascinating growth story.”

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is one of the leading private healthcare services providers in the UAE with a growing presence in Oman and the GCC. With a network of 61 assets, including 39 hospitals and medical centers, as well as pharmacies and other allied services, the Group provides the highest standard of patient care in the region.

For more information visit: https://burjeelholdings.com/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Burjeel Holdings
M Unnikrishnan
Corporate Communications Officer, +971504275895
krish@burjeelholdings.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release

Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital

Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 10:30:00 EEST | Press release

Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h

LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 09:16:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include: LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Si

Sofinnova Partners Appoints David Evans as Partner13.7.2026 09:00:00 EEST | Press release

Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye